10. Lucemyra

US WorldMeds Lucemyra product shot
(US WorldMeds and Salix)

Active ingredient: lofexidine hydrochloride 
Disease: opioid withdrawal symptoms 
Peak sales: N/A  
Approved: May 16 
Company: US WorldMeds

The scoop: Excruciating symptoms of opioid withdrawal can prevent people addicted to opioids from getting off the painkillers. Lucemyra, which has been used for more than two decades in the U.K., was approved to help make the withdrawal process easier for U.S. patients. The drug itself isn’t meant to treat opioid addiction or curb drug cravings. But it can be used as part of a long-term plan toward eventually quitting opioids. National Institute on Drug Abuse Director Nora Volkow, M.D., argues that it could boost wider use of Alkermes’ Vivitrol, a nonopioid addiction treatment that blocks the intoxication effects, by helping patients stick to the detoxification therapies. Lucemyra is currently approved for no more than 14 days of treatment, but more studies are underway, including examining its long-term use. US WorldMeds signed a deal with Bausch Health’s Salix Pharmaceuticals to co-promote Lucemyra. The pair launched the drug in August with a copay program that provides it to eligible patients for as little as $25. — Angus Liu

10. Lucemyra

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.